Mission Wealth Management LP Sells 1,525 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mission Wealth Management LP decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 45.9% during the 4th quarter, Holdings Channel reports. The firm owned 1,800 shares of the company’s stock after selling 1,525 shares during the quarter. Mission Wealth Management LP’s holdings in Neurocrine Biosciences were worth $237,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in shares of Neurocrine Biosciences by 120.6% in the third quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock valued at $65,761,000 after buying an additional 319,564 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Neurocrine Biosciences by 73.0% in the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after acquiring an additional 273,952 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Neurocrine Biosciences by 59.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock worth $77,892,000 after purchasing an additional 256,920 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Neurocrine Biosciences by 86.0% during the third quarter. Jennison Associates LLC now owns 409,475 shares of the company’s stock valued at $46,066,000 after purchasing an additional 189,345 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Neurocrine Biosciences by 81.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company’s stock valued at $54,035,000 after purchasing an additional 184,660 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Up 0.6 %

Shares of NBIX stock opened at $140.71 on Friday. The company has a market capitalization of $14.16 billion, a price-to-earnings ratio of 38.76 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $148.37. The firm has a fifty day moving average of $137.37 and a 200-day moving average of $128.78.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 earnings per share. On average, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. The Goldman Sachs Group upped their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Mizuho upped their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday. BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a report on Thursday. Finally, Guggenheim raised their target price on shares of Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday. Six analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $147.88.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider David W. Boyer sold 456 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total transaction of $64,733.76. Following the sale, the insider now directly owns 4,894 shares of the company’s stock, valued at approximately $694,752.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a total value of $28,000.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at $1,050,980. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David W. Boyer sold 456 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total transaction of $64,733.76. Following the transaction, the insider now owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. Insiders sold 181,547 shares of company stock valued at $25,039,887 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.